BioAffinity Technologies reported a Q1 2025 results profile characterized by a modest top-line gain in a still-nascent revenue base, offset by meaningful operating losses and a tight liquidity position. Revenue for the quarter was $1.854 million, down 22.9% year-over-year and 16.0% quarter-over-quarter, with a gross profit of $0.486 million and a gross margin of 26.2%. The company continues to invest in R&D and SG&A to develop its CyPath lung diagnostic and broader oncology programs, contributing to an operating loss of $2.627 million and an EBITDA of negative $2.482 million. Net income came in at a loss of $2.66 million, or -$0.16 per share on 16.257 million weighted-average shares. The operating cash flow deficit was $1.641 million, and free cash flow was -$1.692 million, leaving a cash balance of $0.445 million at period end, underscoring a fragile liquidity runway absent external financing.
The quarter demonstrates a classic early-stage diagnostics profile: a scalable but still-low revenue product (CyPath lung) in a market requiring reimbursements, regulatory clearances, and scale-driven adoption. While gross margins are encouraging at about 26%, the company faces sustained cash burn as it funds development and commercialization activities. Management commentary from the earnings materials is not embedded in the provided transcript data, limiting color on near-term catalysts or guidance. Investors should monitor the company’s liquidity runway, the pace of CyPath Lung adoption, potential strategic partnerships or licensing agreements, and any new grant or collaboration funding that could alter the financing dynamics and optionality for capital raises.